DANISH BIO – DANSK BIOTEK organizes four major plenary meetings for our members throughout the year to increase our members' knowledge regarding specific biotech topics and to facilitate networking. The events usually take place in February, May, September and November.

We also organize approximately four "saloon" meetings annually. They are small, intimate, "meet the expert" meetings with typically 6-20 participants advocating more in-depth discussion and knowledge-sharing on specific themes.

26 Oct 2020

Y-mAbs Announces FDA Clearance of IND for its Lutetium-177 Labeled Omburtamab Antibody for Adult Indications

Y-mAbs, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer announced today that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational New Drug (“IND”) application for ¹⁷⁷Lu-omburtamab-DTPA for the treatment of medulloblastoma, which is the most common type of primary brain cancer in children. Medulloblastomas are invasive, rapidly growing tumors that, unlike most brain tumors, spread through the cerebrospinal fluid and frequently metastasize to different locations along the surface of the brain and spinal cord.

Read full press release here

Y-mAbs Announces FDA Clearance of IND for its Lutetium-177 Labeled Omburtamab Antibody

Search DANISH BIO – DANSK BIOTEK

26 Oct 2020

Y-mAbs Announces FDA Clearance of IND for its Lutetium-177 Labeled Omburtamab Antibody for Adult Indications